Clinical Study
Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement
Table 1
Patients' Baseline Characteristics (
).
| | Sex (Male/Female) | 10/5 | | Age at diagnosis | 32.1 (19–52) | | median (range) (years) | | Age at start of the therapy | 37.2 (20–64) | | median (range) (years) | | Disease duration | 5.7 (0.1–21) | | median (range) (years) | | Extent of disease | | | L1 (%) | 3 (20.0%) | | L2 (%) | 7 (46.7%) | | L3 (%) | 5 (33.3%) | | Perianal disease (%) | 6 (40.0%) | | Previous surgical resection (%) | 3 (20.0%) | | Concomitant medication | | | Predonisolone | 5 | | 5-Aminosalicylates | 12 | | Immunosuppresants (AZA) | 4 | | GMA | 5 | | Enteral nutrition | 4 | | Anti-TNFa | 0 |
|
|
AZA: azathioprine; GMA: granulocyte and monocyte adsorptive apheresis; L1: Ileum; L2: Colon; L3: Ileocolon.
aPrevious use of infliximab or biologic.
|
